Novelion Therapeutics Inc. Common Shares
NVLN
NVLN was delisted on the 8th of October, 2019.
72 hedge funds and large institutions have $99.3M invested in Novelion Therapeutics Inc. Common Shares in 2017 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 21 increasing their positions, 17 reducing their positions, and 10 closing their positions.
24% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 17
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
5% less funds holding
Funds holding: 76 → 72 (-4)
27% less capital invested
Capital invested by funds: $135M → $99.3M (-$36M)
40% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 10
100% less call options, than puts
Call options by funds: $3K | Put options by funds: $632K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EIG
EdgePoint Investment Group
Toronto,
Ontario, Canada
|
+$8.32M |
| 2 |
Morgan Stanley
New York
|
+$4.84M |
| 3 |
Charles Schwab
San Francisco,
California
|
+$881K |
| 4 |
HVC
Healthcare Value Capital
Woodcliff Lake,
New Jersey
|
+$401K |
| 5 |
State Street
Boston,
Massachusetts
|
+$238K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$6.92M |
| 2 |
TLCM
Tiger Legatus Capital Management
New York
|
-$4.15M |
| 3 |
AA
Ancora Advisors
Cleveland,
Ohio
|
-$2.95M |
| 4 |
HCM
Highbridge Capital Management
New York
|
-$2.39M |
| 5 |
Renaissance Technologies
New York
|
-$1.35M |
NVLN Hedge Fund Activity: Q3 2017 in Review
72 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Novelion Therapeutics Inc. Common Shares (NVLN) for Q3 2017, worth a combined $99.3M — down 27% from $135M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of NVLN and 6 opened new positions — a net loss of 4 holders — while 17 trimmed existing stakes and 21 added.
The largest buyer was EdgePoint Investment Group, opening a new position worth an estimated $8.32M. The largest seller was Opaleye Management, exiting entirely with an estimated $6.92M sold.
- 72 institutional investors held Novelion Therapeutics Inc. Common Shares (NVLN) as of Q3 2017, down from 76 in Q2 2017.
- Funds reported $99.3M of Novelion Therapeutics Inc. Common Shares stock for Q3 2017, down 27% quarter-over-quarter.
- 6 funds opened new Novelion Therapeutics Inc. Common Shares positions in Q3 2017 and 10 closed out, a net change of -4 holders.
- The largest Novelion Therapeutics Inc. Common Shares buyer in Q3 2017 was EdgePoint Investment Group, an estimated $8.32M added.
- The largest Novelion Therapeutics Inc. Common Shares seller in Q3 2017 was Opaleye Management, an estimated $6.92M sold.
Based on aggregated 13F filings for Q3 2017.